Article information
Resumen
Los tratamientos farmacológicos del cáncer cursan con neutropenia en un elevado porcentaje de casos. La utilización de factores estimulantes de colonias de granulocitos (G-CSF) puede evitar las complicaciones asociadas a la neutropenia. Las guías clínicas europeas y americanas recomiendan su uso profiláctico cuando se espera una incidencia de neutropenia febril (NF) mayor del 20% con el tratamiento antineoplásico, o cuando existen factores de riesgo adicionales. Su utilización se recomienda para tratar episodios de NF pero no episodios neutropénicos afebriles. Otras indicaciones aprobadas son la movilización de células madre previa al tratamiento quimioterápico de altas dosis y para la correcta cumplimentación de la farmacoterapia programada en términos de densidad de dosis e intensidad de dosis.
Palabras clave:
Farmacoterapia antineoplásica
Cáncer
Neutropenia
Fiebre neutropénica
Factores estimulantes de colonias de granulocitos
G-CSF
Abstract
Neutropenia is a frequent adverse event of the pharmacologic treatment of cancer. Morbidity and mortality-associated neutropenia can be successfully treated and prevented with granulocyte-colony stimulating factors (G-CSF). European and American Guidelines recommend their prophylactic use when the expected percentage of febrile neutropenia exceeds 20% or there are concomitant risk factors. Afebrile neutropenia is not considered to benefit from G-CSF treatment. Other approved indications include stem cell mobilization, and an adequate delivery of dose-intense and dose-dense chemotherapy regimens.
Keywords:
Anticancer pharmacologic treatment
Cancer
Neutropenia
Neutropenic fever
Granulocyte colony stimulating factors
G-CSF
Full text is only aviable in PDF
Bibliografía
[1.]
N.M. Kuderer, D.C. Dale, J. Crawford, et al.
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.
Cancer, 106 (2006), pp. 2258-2266
[2.]
V. Caggiano, R.V. Weiss, T.S. Rickert, et al.
Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy.
Cancer, 103 (2005), pp. 1916-1924
[3.]
G.H. Lyman, N.M. Kuderer, B. Djulbegovic.
Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis.
Am J Med, 112 (2002), pp. 406-411
[4.]
N.M. Kuderer, D.C. Dale, J. Crawford, G.H. Lyman.
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.
J Clin Oncol, 25 (2007), pp. 3158-3167
[5.]
T.J. Smith, J. Khatcheressian, G.H. Lyman, et al.
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
J Clin Oncol, 24 (2006), pp. 3187-3205
[6.]
J. Crawford, B. Althaus, J. Armitage, et al.
Myeloid growth factors. Clinical practice guidelines in oncology.
J Natl Compr Canc Netw, 5 (2007), pp. 188-202
[7.]
R. Greil, O. Psenak, F. Roila.
ESMO Guidelines working group. ESMO recommendations for the applications.
Ann Oncol, 19 (2008), pp. ii116-ii118
[8.]
M.S. Aapro, D.A. Cameron, R. Pettengell, et al.
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
Eur J Cancer, 42 (2006), pp. 2433-2453
[9.]
A. Carrato Mena, L. Paz Ares, A. Rodríguez Lescure, et al.
Spanish Society of Medical Oncology consensus for the use of hae-matopoietic colony-stimulating factors in cancer patients.
Clin Transl Oncol, 11 (2009), pp. 446-454
[10.]
C.L. Vogel, M.Z. Wojtukiewicz, R.R. Carroll, et al.
First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicentre, doubleblind, placebo controlled phase III study.
J Clin Oncol, 23 (2005), pp. 1178-1184
[11.]
J.N. Timmer-Bonte, T.M. de Boo, H.J. Smit, et al.
Prevention of chemotherapy induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small cell lung cancer: a Dutch Randomized Phase III Study.
J Clin Oncol, 23 (2005), pp. 7974-7984
[12.]
J.L. Gabrilove, A. Jakubowski, H. Scher, et al.
Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium.
N Engl J Med, 318 (1988), pp. 1414-1422
[13.]
M. Martin, A. Lluch, M.A. Segui, et al.
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.
Ann Oncol, 17 (2006), pp. 1205-1212
[14.]
L. Norton, R. Simon.
The Norton-Simon hypothesis revisited.
Cancer Treat Rep, 70 (1986), pp. 163-169
[15.]
M.L. Citron, D.A. Berry, C. Cirrincione, et al.
Randomized trial of dose dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
J Clin Oncol, 21 (2003), pp. 1431-1439
[16.]
M. Pfreundschuh, J. Schubert, M. Ziepert, et al.
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60).
Lancet Oncol, 9 (2008), pp. 84-86
[17.]
M. Pfreundschuh, L. Trümper, M. Kloess, et al.
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.
Blood, 104 (2004), pp. 626-633
[18.]
S.D. Scott, E.A. Chrischilles, B.K. Link, et al.
Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy.
J Manag Care Pharm, 9 (2003), pp. 15-21
[19.]
D. Almenar, J. Mayans, O. Juan, et al.
Pegfilgrastim and daily granulocyte colony-stimulating factor (G-CSF). Patterns of use and neutropenia related outcomes in cancer patients in Spain: results of the Learn Study.
Blood, 106 (2005),
[20.]
G.H. Lyman, N.M. Kuderer.
Epidemiology of febrile neutropenia.
Supp Cancer Ther, 1 (2003), pp. 23-25
[21.]
J. Crawford, D.C. Dale, G.H. Lyman.
Chemotherapy-induced neu-tropenia: risks, consequences, and new directions for its mana-gement.
Cancer, 100 (2004), pp. 228-237
[22.]
L. Repetto.
Greater risks of chemotherapy toxicity in elderly patients with cancer.
J Supp Oncol, 4 (2003), pp. 18-24
[23.]
S.M. Lichtman, J.A. Skirvin, S. Vemulapalli.
Pharmacology of antineoplastic agents in older cancer patients.
Crit Rev Oncol Hematol, 46 (2003), pp. 101-114
[24.]
L. Balducci, M. Extermann.
Management of cancer in the older person: a practical approach.
Oncologist, 5 (2005), pp. 224-237
[25.]
M. Bower, N. McCall-Peat, N. Ryan, et al.
Protease inhibitors potentiate chemotherapy-induced neutropenia.
Blood, 104 (2004), pp. 2943-2946
[26.]
A.W. Harbol, J.L. Liesveld, P.J. Simpson-Haidaris, C.N. Abboud.
Mechanisms of cytopenia in human immunodeficiency virus infection.
Blood Rev, 8 (1994), pp. 241-251
[27.]
J.A. Talcott, R.D. Siegel, R. Finberg, L. Goldman.
Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule.
J Clin Oncol, 10 (1992), pp. 316-322
[28.]
J. Klastersky, M. Paesmans, E.B. Rubenstein, et al.
The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients.
J Clin Oncol, 18 (2000), pp. 3038-3051
[29.]
O.A. Clark, G.H. Lyman, A.A. Castro, et al.
Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials.
J Clin Oncol, 23 (2005), pp. 4198-4214
[30.]
L.C. Hartmann, L.K. Tschetter, T.M. Habermann, et al.
Granulocyte colonystimulating factor in severe chemotherapy-induced afebrile neutropenia.
N Engl J Med, 336 (1997), pp. 1776-1780
Copyright © 2010. Sociedad Española de Farmacia Hospitalaria
